No abstract available
Publication types
-
Letter
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Age Factors
-
Anticoagulants / administration & dosage
-
Anticoagulants / adverse effects
-
Anticoagulants / blood
-
Anticoagulants / pharmacokinetics*
-
Aryl Hydrocarbon Hydroxylases / genetics*
-
Aryl Hydrocarbon Hydroxylases / metabolism
-
Biotransformation
-
Blood Coagulation / drug effects*
-
Child
-
Child, Preschool
-
Cross-Sectional Studies
-
Cytochrome P-450 CYP2C9
-
Drug Monitoring / methods
-
England
-
Female
-
Gene Frequency
-
Genetic Predisposition to Disease
-
Hemorrhage / chemically induced
-
Hemorrhage / genetics
-
Humans
-
Infant
-
International Normalized Ratio
-
Male
-
Mixed Function Oxygenases / genetics*
-
Mixed Function Oxygenases / metabolism
-
Ontario
-
Pharmacogenetics
-
Phenotype
-
Retrospective Studies
-
Risk Factors
-
Vitamin K Epoxide Reductases
-
Warfarin / administration & dosage
-
Warfarin / adverse effects
-
Warfarin / blood
-
Warfarin / pharmacokinetics*
Substances
-
Anticoagulants
-
Warfarin
-
Mixed Function Oxygenases
-
CYP2C9 protein, human
-
Cytochrome P-450 CYP2C9
-
Aryl Hydrocarbon Hydroxylases
-
VKORC1 protein, human
-
Vitamin K Epoxide Reductases